Autoimmune Diseases

Aurinia Pharmaceuticals will present Phase 1 study results for its investigational therapy AUR200 on June 30, 2025. The company, focused on autoimmune diseases, previously launched LUPKYNIS and is developing AUR200 as a dual inhibitor targeting BAFF and APRIL. The findings will be shared via webcast and conference call.

BioNxt Solutions has secured a pivotal European patent for its sublingual drug delivery platform, enhancing its intellectual property position for treating autoimmune diseases. The technology underpins BNT23001, a fast-dissolving oral film of Cladribine aimed at revolutionizing multiple sclerosis therapy by replacing injections with a needle-free, bioavailable alternative. Global patent filings are advancing in the U.S., Japan, and Eurasia, targeting a $150B+ autoimmune market. Upcoming bioequivalence studies in 2025 could enable accelerated EU approval. The platform also shows potential for lupus and arthritis treatments, with preclinical data suggesting improved delivery of biologic agents, positioning BioNxt as a leader in precision drug reformulation.

GRI Bio (NASDAQ: GRI), a San Diego-based biotech targeting iNKT cells for autoimmune therapies, will present its immunomodulatory platform at A.G.P.’s 2025 Healthcare Showcase on May 21 (2:40 PM ET) via live webcast. Dr. Marc Hertz, CEO, will outline advancements over traditional CAR-T approaches and highlight upcoming Phase II results for GRI-0621 (IPF/lupus pipelines) and its 500-compound library. The event attracts 500+ investors and historically correlates with 8% stock performance gains, offering critical visibility for the company’s early-inflammation intervention strategy. [99 words]